Salix Pharmaceuticals, a maker of gastrointestinal drugs that has been courted by at least four potential suitors over the last year, has finally found a buyer.
Valeant Pharmaceuticals, the acquisitive Canadian pharmaceutical company, has agreed to pay US$10.4 billion for Salix, or US$158 a share in cash. Including debt, the transaction is valued at about US$14.5 billion.
The deal is a turning point for both companies.
For Valeant, which spent the better part of last year unsuccessfully trying to acquire Allergan, the maker of Botox, the acquisition represents a return to form for the company and its chief executive, Michael Pearson.
Valeant is known as an aggressive buyer of smaller drug companies, and failing to secure Allergan, even with the help of hedge fund billionaire William Ackman, was a rare defeat.
And for Salix, which has been courted by Allergan, Actavis and Shire in recent months, the sale to Valeant will put an end to constant deal speculation.
Salix’s share price has risen steadily as speculation of a deal intensified, jumping more than 50 percent in the last three months alone. Sales of the company’s more than 22 drugs, which include Xifaxan, Uceris, Relistor and Apriso, have been growing rapidly. Revenue for this year is expected to exceed US$1.4 billion.
However, Salix, based in Raleigh, North Carolina, has also had trouble with overstocked inventory for its drugs in recent months. Valeant believes it can manage the issues once it owns the company.
By acquiring Salix, Valeant gains another set of products it can plug into its expanding sales pipeline. Valeant is known for acquiring products and expanding their sales, instead of spending billions on research and development in hopes of discovering lucrative new drugs.
Among the deals that have given Valeant a market value of more than US$58 billion was the acquisition of Bausch & Lomb, the eye care company, in 2013 for about US$8.7 billion.
This deal is an unusual turn of events for Valeant. Last year, as Valeant was pressuring Allergan to agree to a deal, Salix nearly played spoiler. Allergan almost acquired Salix late in the summer, a deal that would probably have made Allergan too expensive for Valeant.
However, Allergan never bough Salix, agreeing to sell itself to Actavis for US$66 billion and leaving Valeant on the sidelines during a banner year for healthcare dealmaking.
Salix and Valeant said the combination would lead to cost savings of at least US$500 million within six months, mostly through reducing corporate overhead and research and development spending. They expected the deal to close in the second quarter of this year.
Though some jobs will be in jeopardy at Salix, Valeant said it did not plan any immediate reductions to Salix’s specialty sales force.
Pearson also said Valeant would save money by reducing Salix’s tax rate. Valeant has an effective tax rate of just 4 percent.
In a conference call with analysts and investors scheduled for yesterday morning, Valeant executives will discuss its fourth quarter and full year results and the deal.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by